Gérard Zalcman
0000-0002-0343-9575
Centre de Recherche Institut Curie
422 papers found
Refreshing results…
Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitors
Three cancer associated fibroblasts subtypes are associated with histological features, immune environment and prognosis in resected non-small cell lung cancer (NSCLC)
Préconisations pour protéger les patients de la filière oncologique face au variant Omicron
Thoracic CT follow-up after non-small-cell lung cancer resection
Precise and fast control of the dissolved oxygen level for tumor-on-chip
Transthoracic lung biopsy for pulmonary nodules ≤20 mm in routine clinical care
378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma
Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway
LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations
1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)
NKX2.1 (TTF1) germline mutation associated with pulmonary fibrosis and lung cancer
Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.
Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.
Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Apoptosis mapping in space and time of 3D tumor ecosystems reveals transmissibility of cytotoxic cancer death
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
Missing publications? Search for publications with a matching author name.